Machine and deep learning approaches for cancer drug repurposing

• Published in: Seminars in cancer biology Vol. 68; pp. 132 - 142
• Main Authors: Issa, Naiem T., Stathias, Vasileios, Schürer, Stephan, Dakshanamurthy, Sivanesan
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2021
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Artificial Intelligence; Computational Biology - methods; Deep Learning; Drug Discovery; Drug Repositioning - methods; Drug repurposing; Humans; Machine Learning; Neoplasms - drug therapy; ADE; CNN; MDSC; DNN; Drug repurposing; SVM; ADMET; EMT; EHR; ICI; TCGA; Deep learning; NLP; RF; QSAR; TIL; Machine learning; PCM; Drug discovery; Artificial intelligence
• ISSN: 1044-579X; 1096-3650
• DOI: 10.1016/j.semcancer.2019.12.011

Knowledge of the underpinnings of cancer initiation, progression and metastasis has increased exponentially in recent years. Advanced “omics” coupled with machine learning and artificial intelligence (deep learning) methods have helped elucidate targets and pathways critical to those processes that may be amenable to pharmacologic modulation. However, the current anti-cancer therapeutic armamentarium continues to lag behind. As the cost of developing a new drug remains prohibitively expensive, repurposing of existing approved and investigational drugs is sought after given known safety profiles and reduction in the cost barrier. Notably, successes in oncologic drug repurposing have been infrequent. Computational in-silico strategies have been developed to aid in modeling biological processes to find new disease-relevant targets and discovering novel drug-target and drug-phenotype associations. Machine and deep learning methods have especially enabled leaps in those successes. This review will discuss these methods as they pertain to cancer biology as well as immunomodulation for drug repurposing opportunities in oncologic diseases.